Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZYTIGA | Johnson & Johnson | N-202379 RX | 2011-04-28 | 2 products, RLD |
YONSA | sparc | N-210308 RX | 2018-05-22 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AKEEGA | Johnson & Johnson | N-216793 RX | 2023-08-11 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
abiraterone | ANDA | 2023-12-27 |
abiraterone acetate | ANDA | 2024-01-15 |
akeega | New Drug Application | 2023-08-22 |
yonsa | Export only | 2023-11-16 |
zytiga | New Drug Application | 2021-10-14 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
castration-resistant prostatic neoplasms | — | D064129 | — |
Expiration | Code | ||
---|---|---|---|
ABIRATERONE ACETATE / NIRAPARIB TOSYLATE, AKEEGA, JANSSEN BIOTECH | |||
2026-08-11 | NP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Abiraterone Acetate / Niraparib Tosylate, Akeega, Janssen Biotech | |||
11091459 | 2038-03-27 | DS, DP | |
11673877 | 2038-03-27 | DS, DP | |
11207311 | 2037-07-28 | U-2830 | |
8859562 | 2031-08-04 | U-2830 | |
8071623 | 2031-03-27 | DS, DP | |
8436185 | 2029-04-24 | DS, DP | |
8071579 | 2027-08-12 | U-2830 | |
8143241 | 2027-08-12 | U-2830 | |
Abiraterone Acetate, Yonsa, Sun Pharm | |||
10292990 | 2034-05-20 | U-2535 | |
9889144 | 2034-03-17 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 55 | 137 | 27 | 4 | 30 | 231 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 33 | 55 | 16 | 4 | 12 | 102 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | 2 | 17 | 1 | — | 2 | 22 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 4 | 1 | — | — | 8 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 3 | — | 1 | 4 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | 1 | — | 1 | 2 |
Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 6 | 5 | — | — | — | 8 |
Non-small-cell lung carcinoma | D002289 | — | — | 6 | 3 | — | — | — | 7 |
Colorectal neoplasms | D015179 | — | — | 5 | 2 | — | — | — | 5 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 3 | — | — | — | 3 |
Triple negative breast neoplasms | D064726 | — | — | 3 | 1 | — | — | — | 3 |
Neoadjuvant therapy | D020360 | — | — | — | 3 | — | — | — | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 1 | — | — | — | 2 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 2 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 2 |
Congenital adrenal hyperplasia | D000312 | — | E25.0 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disease resistance | D060467 | — | — | — | — | — | — | 1 | 1 |
Pharmacogenomic testing | D000071185 | — | — | — | — | — | — | 1 | 1 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
Supraventricular tachycardia | D013617 | HP_0004755 | I47.1 | — | — | — | — | 1 | 1 |
Male genital diseases | D005832 | EFO_0009555 | N50.9 | — | — | — | — | 1 | 1 |
Male genital neoplasms | D005834 | — | — | — | — | — | — | 1 | 1 |
Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Abiraterone |
INN | abiraterone |
Description | Abiraterone acetate is a sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. It has a role as a prodrug, an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a sterol ester and a member of pyridines. It is functionally related to an abiraterone. |
Classification | Small molecule |
Drug class | antiandrogens |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1 |
PDB | — |
CAS-ID | 154229-19-3 |
RxCUI | — |
ChEMBL ID | CHEMBL254328 |
ChEBI ID | 68642 |
PubChem CID | 9821849 |
DrugBank | DBSALT001173 |
UNII ID | G819A456D0 (ChemIDplus, GSRS) |